Atria Investments Inc Purchases 6,440 Shares of Intuitive Surgical, Inc. $ISRG

Atria Investments Inc lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 21.8% during the 4th quarter, Holdings Channel reports. The firm owned 35,939 shares of the medical equipment provider’s stock after acquiring an additional 6,440 shares during the period. Atria Investments Inc’s holdings in Intuitive Surgical were worth $20,354,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Draper Asset Management LLC boosted its stake in shares of Intuitive Surgical by 41.9% in the 4th quarter. Draper Asset Management LLC now owns 5,029 shares of the medical equipment provider’s stock worth $2,848,000 after buying an additional 1,485 shares during the last quarter. Atlantic Union Bankshares Corp boosted its stake in shares of Intuitive Surgical by 19.3% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 22,759 shares of the medical equipment provider’s stock worth $10,179,000 after buying an additional 3,676 shares during the last quarter. Valley Wealth Managers Inc. boosted its stake in shares of Intuitive Surgical by 52.7% in the 3rd quarter. Valley Wealth Managers Inc. now owns 4,084 shares of the medical equipment provider’s stock worth $1,826,000 after buying an additional 1,409 shares during the last quarter. AGF Management Ltd. boosted its position in Intuitive Surgical by 0.6% in the third quarter. AGF Management Ltd. now owns 464,179 shares of the medical equipment provider’s stock worth $207,595,000 after purchasing an additional 2,575 shares during the last quarter. Finally, AE Wealth Management LLC boosted its position in Intuitive Surgical by 18.9% in the third quarter. AE Wealth Management LLC now owns 11,556 shares of the medical equipment provider’s stock worth $5,168,000 after purchasing an additional 1,836 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In other news, SVP Mark Brosius sold 645 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $485.01, for a total value of $312,831.45. Following the completion of the sale, the senior vice president directly owned 1,613 shares of the company’s stock, valued at $782,321.13. This represents a 28.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Myriam Curet sold 105 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $493.95, for a total transaction of $51,864.75. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 5,647 shares of company stock valued at $2,760,359. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $432.27 on Thursday. The firm has a fifty day moving average price of $466.62 and a 200-day moving average price of $515.53. The stock has a market cap of $153.09 billion, a PE ratio of 52.40, a price-to-earnings-growth ratio of 3.45 and a beta of 1.51. Intuitive Surgical, Inc. has a 1 year low of $417.74 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.42. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.81 earnings per share. On average, research analysts expect that Intuitive Surgical, Inc. will post 8.57 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ISRG. Argus dropped their target price on Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Citigroup raised Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 target price on the stock in a research report on Wednesday, March 11th. The Goldman Sachs Group raised their target price on Intuitive Surgical from $609.00 to $621.00 and gave the stock a “buy” rating in a research report on Wednesday, April 22nd. Leerink Partners dropped their target price on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Finally, Evercore dropped their target price on Intuitive Surgical from $550.00 to $480.00 and set a “neutral” rating on the stock in a research report on Monday, April 6th. Eighteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $581.91.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.